Watch IMA. Know when insiders buy.
One email the day a filing lands. Free.
IMA
ImageneBio, Inc.
5.02
+0.09 +1.83%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $57MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$52.5MNET CASH $94.7M52W 4.55 – 8.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$11.8M | −$10.2M | — | -0.63 | −$9.1M | — | — | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$12.1M | −$10.6M | — | -0.95 | −$14.8M | — | — | Aug 5 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$8.5M | −$6.9M | — | 0.34 | −$7.2M | — | — | Mar 10 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$26.6M | −$24.8M | — | -2.91 | −$21.5M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $0 | — | — | −$7.4M | −$7.6M | — | -4.46 | −$11.9M | — | — | Aug 5 |
| Q1 2025 · Mar 31 | $800K | — | — | −$6M | −$6.1M | — | -3.80 | −$7.2M | — | — | Aug 5 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$6.1M | −$4.8M | — | -2.96 | −$3.5M | — | — | Mar 10 |
| Q3 2024 · Sep 30 | $3.5M | +195.4% | — | −$2M | −$3.2M | — | -2.58 | $13M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$15.8M | −$6.3M | — | -0.28 | −$12.5M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$18.2M | −$22.3M | — | -0.33 | −$18.3M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $659K | — | — | −$21.9M | −$19.5M | — | -0.40 | −$21.8M | $262K | −$22.1M | Mar 6 |
| Q3 2023 · Sep 30 | $1.2M | — | — | −$19.5M | −$17.3M | — | -0.40 | −$20M | $0 | −$20M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $800K | — | −$48.5M | −$45.3M | -5668.6% | -9.64 | −$47.8M | — | — | — | — |
| FY2024 · to Dec 31 | $3.5M | — | −$37M | −$36.6M | -1044.8% | -22.10 | −$21.3M | — | — | — | — |
| FY2023 · to Dec 31 | $9.2M | — | −$75.4M | −$68.2M | -744.2% | -1.63 | −$79.7M | $414K | −$80.2M | $663K | — |
| FY2022 · to Dec 31 | $15.6M | — | −$70.9M | −$68.8M | -440.3% | -1.90 | −$74.1M | $1.4M | −$75.5M | — | — |
| FY2021 · to Dec 31 | $31M | — | −$34.1M | −$34.1M | -110.1% | -1.22 | −$60.3M | $1.8M | −$62M | — | — |
| FY2020 · to Dec 31 | $9.2M | — | −$44.5M | −$44.3M | -481.4% | -16.00 | −$37.8M | $766K | −$38.6M | — | — |
Every number comes from ImageneBio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.